Human Metabolome Technologies, Inc. (TYO:6090)
623.00
-2.00 (-0.32%)
Aug 27, 2026, 12:32 PM JST
TYO:6090 Revenue
In the fiscal year ending June 30, 2026, Human Metabolome Technologies had annual revenue of 1.42B JPY, down -2.34%. Human Metabolome Technologies had revenue of 314.00M in the quarter ending June 30, 2026, with 66.14% growth.
Revenue
1.42B
Revenue Growth
-2.34%
P/S Ratio
2.45
Revenue / Employee
22.92M
Employees
62
Market Cap
3.48B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 1.42B | -34.00M | -2.34% |
| Jun 30, 2025 | 1.46B | 110.00M | 8.18% |
| Jun 30, 2024 | 1.35B | 46.00M | 3.54% |
| Jun 30, 2023 | 1.30B | 76.00M | 6.21% |
| Jun 30, 2022 | 1.22B | 99.00M | 8.81% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 13.64B |
| Kohjin Bio | 4.69B |
| Kringle Pharma | 342.21M |
| Cyfuse Biomedical K.K. | 305.00M |
| D. Western Therapeutics Institute | 247.00M |
| Veritas In Silico | 84.42M |
| Ribomic | 7.50M |
| FunPep Company | 1.00M |